Deltagen (DGEN) Reports 2012 Fourth Quarter and Full-Year Financial Results
4/11/2013 6:54:38 AM
Deltagen, Inc. (Pink Sheets: DGEN), a leading provider of drug discovery tools and services to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months and year ended December 31, 2012.
Revenues: The Company’s consolidated revenues for the three months and year ended December 31, 2012 totaled $0.133 million and $1.054 million, respectively. The revenues in the fourth quarter and in 2012 were attributable to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the Company’s DeltaOneTM program.